Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas.
about
Prophylactic human papillomavirus vaccinesIdentification of human papillomavirus type 16 L1 surface loops required for neutralization by human seraCurrent understanding of the mechanism of HPV infectionVirus-like particles production in green plantsCharacterization of HPV16 L1 loop domains in the formation of a type-specific, conformational epitopeHPV Associated Head and Neck CancerHuman papillomavirus vaccination: a case study in translational scienceDiscussing the diagnosis of HPV-OSCC: common questions and answersThe Canine Papillomavirus E5 Protein Signals from the Endoplasmic ReticulumModulation of therapeutic sensitivity by human papillomavirusCapsomer vaccines protect mice from vaginal challenge with human papillomavirusAncient papillomavirus-host co-speciation in FelidaeThe potential impact of prophylactic human papillomavirus vaccination on oropharyngeal cancer.Virus-like particles: a new family of delivery systems.Identification of neutralizing conformational epitopes on the human papillomavirus type 31 major capsid protein and functional implicationsPapillomavirus prophylactic vaccines: established successes, new approaches.Increased immunoaccessibility of MOMP epitopes in a vaccine formulated with amphipols may account for the very robust protection elicited against a vaginal challenge with Chlamydia muridarum.The L1 major capsid protein of human papillomavirus type 16 variants affects yield of virus-like particles produced in an insect cell expression system.Complete genome sequence of canine papillomavirus type 11.Expression of HPV-16 L1 capsomeres with glutathione-S-transferase as a fusion protein in tobacco plastids: an approach for a capsomere-based HPV vaccine.Immunogenicity assessment of HPV16/18 vaccine using the glutathione S-transferase L1 multiplex serology assay.Skin vaccination against cervical cancer associated human papillomavirus with a novel micro-projection array in a mouse model.Papillomavirus pseudovirions packaged with the L2 gene induce cross-neutralizing antibodiesVaccine prevention of cancer: can endogenous antigens be targeted?Nasal immunization of mice with human papillomavirus type 16 virus-like particles elicits neutralizing antibodies in mucosal secretionsHuman papillomavirus type 11 recombinant L1 capsomeres induce virus-neutralizing antibodies.Expression, purification and characterization of enterovirus-71 virus-like particles.Papillomavirus capsid mutation to escape dendritic cell-dependent innate immunity in cervical cancer.Characterization of a major neutralizing epitope on human papillomavirus type 16 L1Nasal immunization of mice with human papillomavirus type 16 (HPV-16) virus-like particles or with the HPV-16 L1 gene elicits specific cytotoxic T lymphocytes in vaginal draining lymph nodesMucosal but not parenteral immunization with purified human papillomavirus type 16 virus-like particles induces neutralizing titers of antibodies throughout the estrous cycle of miceHuman papillomavirus virus-like particles are efficient oral immunogens when coadministered with Escherichia coli heat-labile enterotoxin mutant R192G or CpG DNA.Papillomavirus pseudovirus: a novel vaccine to induce mucosal and systemic cytotoxic T-lymphocyte responses.Immunization with a pentameric L1 fusion protein protects against papillomavirus infection.Measurement of neutralizing serum antibodies of patients vaccinated with human papillomavirus L1 or L2-based immunogens using furin-cleaved HPV Pseudovirions.Humoral immune response recognizes a complex set of epitopes on human papillomavirus type 6 l1 capsomers.Viable adenovirus vaccine prototypes: high-level production of a papillomavirus capsid antigen from the major late transcriptional unit.Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles.Characterization of the HPV-specific memory B cell and systemic antibody responses in women receiving an unadjuvanted HPV16 L1 VLP vaccineEvaluation of systemic and mucosal anti-HPV16 and anti-HPV18 antibody responses from vaccinated women.
P2860
Q24545449-4C075561-F9C7-47DC-858B-0DB081420446Q24545868-669A173F-EC4B-4BC8-AFEF-E43804D74E78Q24616134-1691EDBE-4360-416B-A9DC-485CAD8A02ACQ24650772-F734A247-C124-4D6D-87AB-2E26526A6C07Q24796150-2B170AF1-9F63-48F5-849D-556CFE55ED89Q26741386-7A8C7948-2AFE-4482-B72C-70FBE524411CQ26853556-7A90F682-CAC7-4E3D-BE7F-0A476823CBC4Q27000693-2BA36F68-D026-48E9-BC64-6E0769A2444BQ27490470-406E36B3-DEF5-471F-AC1B-EEFD5D769845Q28087031-D951A028-CF07-4570-93E2-67CAF3E41554Q28743261-2A200330-A572-468E-A431-968EEE6F852EQ28757525-3EC9B5DA-C6F0-49E6-9E54-10D28A177E29Q30251408-FC2F6572-07C4-43A2-8469-E208E2321207Q30817169-12D66797-9257-4AE0-BB5A-236398FD7F9EQ33469751-3D0501BE-9617-4BFB-8BA4-CDD51F05D0ACQ33614425-2E21C132-BA0A-4363-B581-3CE5969BCDB0Q33648677-2E5C6A65-9C2D-472D-9973-717F8689C56BQ33673620-BEE7F54C-45C4-4678-A1DB-9D1A69CFB3E8Q33687407-59E37900-300E-4C20-8829-34FCABA5809AQ33723292-5C4F6851-4128-40D4-9454-E8CE5D74FCFDQ33723312-939EFC65-B89D-400B-BD8D-734B83337769Q33728320-5E7651D2-CA71-425B-8A7F-703CBA3BD910Q33780651-905CA952-53A0-4727-A0AE-B9C76B6266BEQ33783609-E368F407-534C-4DE3-B294-E0E61EC34801Q33784891-7ED0A217-B313-43C1-9002-6989B25C2A32Q33785841-256A4755-2D9E-42F5-9F8D-8B0B50116691Q33788579-CC1E78F1-7D84-4E9C-91F2-A89A6E82D9C0Q33788885-A6AAA570-AD78-4A10-B9D1-6BE7DFA4AB6FQ33813986-B22384D3-E6E8-4443-8FB8-8874ADEE101AQ33822614-84D010D3-1155-4C3A-BA94-C2B8DB26C006Q33823755-0C91DF9B-B303-4DFC-8C5C-3C6E390D78E6Q33840918-576893FC-D7E9-42AD-9209-F158FBF5ECBCQ33847557-339F6AC4-5FC3-472C-9032-7CF241E6D2C8Q33853398-F5CC461A-BF7B-483E-8B5A-CBB91EF19CBCQ33856453-EDD7EC26-05DC-4A97-A9DA-7FA12BED876BQ33908917-F5BAB5FA-CB40-4206-A159-A929B1CD93C2Q33932258-52CF3152-3AC0-4261-9D29-690CAF402FEEQ33967624-2DC7E35B-31BF-4BC9-9392-065E3A516319Q34032367-D00A8A06-E8AB-419A-A74C-9B4ADA9F1649Q34038946-F11029A0-44D1-4B51-AA8C-CAFA6849B84B
P2860
Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas.
description
1995 nî lūn-bûn
@nan
1995 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1995 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
name
Systemic immunization with pap ...... t of viral mucosal papillomas.
@ast
Systemic immunization with pap ...... t of viral mucosal papillomas.
@en
type
label
Systemic immunization with pap ...... t of viral mucosal papillomas.
@ast
Systemic immunization with pap ...... t of viral mucosal papillomas.
@en
prefLabel
Systemic immunization with pap ...... t of viral mucosal papillomas.
@ast
Systemic immunization with pap ...... t of viral mucosal papillomas.
@en
P2093
P2860
P356
P1476
Systemic immunization with pap ...... t of viral mucosal papillomas.
@en
P2093
A B Jenson
F J Palmer-Hill
J A Newsome
J A Suzich
J K Tamura
R Schlegel
P2860
P304
11553-11557
P356
10.1073/PNAS.92.25.11553
P407
P577
1995-12-01T00:00:00Z